{"id":20,"date":"2024-04-04T04:15:08","date_gmt":"2024-04-04T01:15:08","guid":{"rendered":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/37-kasutatud-allikad\/"},"modified":"2024-04-04T04:15:35","modified_gmt":"2024-04-04T01:15:35","slug":"37-kasutatud-allikad","status":"publish","type":"page","link":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/37-kasutatud-allikad\/","title":{"rendered":"3.7. Kasutatud allikad"},"content":{"rendered":"<ol dir=\"ltr\">\n<li>\n\t\tAmeerika \u00dchendriikide Toidu ja Ravimiamet, Geneerilised ravimpreparaadid (Generic Drugs), <a data-url=\"https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/generic-drugs\" href=\"https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/generic-drugs\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/generic-drugs<\/a> (04.09.19)\n\t<\/li>\n<li>\n\t\tEuroopa Direktiiv 2001\/83\/E\u00dc, <a data-url=\"https:\/\/eur-lex.europa.eu\/legal-content\/en\/ALL\/?uri=CELEX%3A32001L0083\" href=\"https:\/\/eur-lex.europa.eu\/legal-content\/en\/ALL\/?uri=CELEX%3A32001L0083\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/eur-lex.europa.eu\/legal-content\/en\/ALL\/?uri=CELEX%3A32001L0083<\/a> (05.09.19)\n\t<\/li>\n<li>\n\t\tEuroopa Ravimiamet, geneerilised ravimpreparaadid (Generic and hybrid medicines), <a data-url=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/generic-hybrid-medicines\" href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/generic-hybrid-medicines\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/generic-hybrid-medicines<\/a> (04.09.19)\n\t<\/li>\n<li>\n\t\tEuroopa Ravimiamet, Head tootmistavad (Good Manufacturing Practice). <a data-url=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-manufacturing-practice\" href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-manufacturing-practice\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-manufacturing-practice<\/a>\n\t<\/li>\n<li>\n\t\tEuroopa Ravimiamet, Head kliiniliste uuringute tavad (Good Clinical Practice). <a data-url=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-clinical-practice\" href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-clinical-practice\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-clinical-practice<\/a>\n\t<\/li>\n<li>\n\t\tEuroopa Ravimiamet, Head laboritavad (Good Laboratory Practice). <a data-url=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-laboratory-practice-compliance\" href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-laboratory-practice-compliance\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-laboratory-practice-compliance<\/a>\n\t<\/li>\n<li>\n\t\tFarmaatsiaterminoloogia andmebaas, <a data-url=\"https:\/\/ravimiamet.ee\/farmaatsiaterminoloogia-andmebaas\" href=\"https:\/\/ravimiamet.ee\/farmaatsiaterminoloogia-andmebaas\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/ravimiamet.ee\/farmaatsiaterminoloogia-andmebaas<\/a> (05.09.19)\n\t<\/li>\n<li>\n\t\tHilfiker. R. (2006). Polymorphism in Pharmaceutical Industry, Wiley-VCH; 1 edition.\n\t<\/li>\n<li>\n\t\tHinrikus, T.; Kogermann, K.; Laius, O.; Leito, S.; Raal, A.; Soosaar, A.; Teppor, T.; Volmer, D. (2017). Farmaatsiaterminite l\u00fchendid, Eesti Arst 96(6):357\u2013363.\n\t<\/li>\n<li>\n\t\tHinrikus, T.; Kogermann, K.; Laius, O.; Leito, S.; Raal, A.; Soosaar, A.; Teppor, T.; Volmer, D. (2019) Farmaatsiaterminoloogia 2 v\u00e4ljaanne.\n\t<\/li>\n<li>\n\t\tMaailma tervishoiuorganisatsioon, INN, <a data-url=\"https:\/\/www.who.int\/teams\/health-product-and-policy-standards\/inn\" href=\"https:\/\/www.who.int\/teams\/health-product-and-policy-standards\/inn\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.who.int\/teams\/health-product-and-policy-standards\/inn<\/a> (04.09.19)\n\t<\/li>\n<li>\n\t\tKogermann, K. (2019). <a data-url=\"https:\/\/heureka.postimees.ee\/6760635\/karin-kogermann-iga-ravim-on-murk-koik-oleneb-annusest-ja-oigest-kasutamisest\" href=\"https:\/\/heureka.postimees.ee\/6760635\/karin-kogermann-iga-ravim-on-murk-koik-oleneb-annusest-ja-oigest-kasutamisest\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/heureka.postimees.ee\/6760635\/karin-kogermann-iga-ravim-on-murk-koik-oleneb-annusest-ja-oigest-kasutamisest<\/a> (05.09.19)\n\t<\/li>\n<li>\n\t\tKogermann, K. (2016). Originaalravimid ja geneerilised ravimid. T\u00e4ienduskonverents Kliinik 2016 (1.-3.02.2016). <a data-url=\"https:\/\/www.uttv.ee\/naita?id=23434&amp;keel=eng\" href=\"https:\/\/www.uttv.ee\/naita?id=23434&amp;keel=eng\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.uttv.ee\/naita?id=23434&amp;keel=eng<\/a> (05.09.19)\n\t<\/li>\n<li>\n\t\tKogermann, K. (2018). Miks ja kuidas tehakse uusi ravimeid? Hambaarst, 60-66.\n\t<\/li>\n<li>\n\t\tPaaver, U.; Kogermann, K. (2015) Ravimvormide terminoloogia ja klassifitseerimine, Eesti Arst 94(4):242\u2013245.\n\t<\/li>\n<li>\n\t\tPaaver, U.; Kogermann, K. (2016). Ravimvormide klassifikatsioon: tabletid (I), Eesti Arst 95(7):479\u2013484.\n\t<\/li>\n<li>\n\t\tRavimiseadus, <a data-url=\"https:\/\/www.riigiteataja.ee\/akt\/104052016004\" href=\"https:\/\/www.riigiteataja.ee\/akt\/104052016004\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.riigiteataja.ee\/akt\/104052016004<\/a>, (04.09.19)\n\t<\/li>\n<li>\n\t\tRavimiamet, Kliiniliste uuringutega seotud \u00f5igusaktid, juhendid ja vormid <a data-url=\"https:\/\/ravimiamet.ee\/oigusaktid-juhendid-vormid\/oigusaktid-juhendid-ja-vormid\/kliinilised-uuringud\" href=\"https:\/\/ravimiamet.ee\/oigusaktid-juhendid-vormid\/oigusaktid-juhendid-ja-vormid\/kliinilised-uuringud\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/ravimiamet.ee\/oigusaktid-juhendid-vormid\/oigusaktid-juhendid-ja-vormid\/kliinilised-uuringud<\/a> (05.09.19)\n\t<\/li>\n<li>\n\t\tSotsiaalministri m\u00e4\u00e4rus nr 28 \u201cRavimi m\u00fc\u00fcgiloa taotluse liigid ja vormin\u00f5uded, t\u00e4iendava dokumentatsiooni loetelu, t\u00e4iendavale dokumentatsioonile esitatavad n\u00f5uded, taotluse erialase hindamise tasu suurus taotluse eri liikide kaupa ning tasu arvestamise ja tasumise kord\u201d, <a data-url=\"https:\/\/www.riigiteataja.ee\/akt\/889251\" href=\"https:\/\/www.riigiteataja.ee\/akt\/889251\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.riigiteataja.ee\/akt\/889251<\/a> (04.09.19)\n\t<\/li>\n<li>\n\t\tSotsiaalministri m\u00e4\u00e4ruse nr 28 \u201cRavimi m\u00fc\u00fcgiloa taotluse liigid ja vormin\u00f5uded, t\u00e4iendava dokumentatsiooni loetelu, t\u00e4iendavale dokumentatsioonile esitatavad n\u00f5uded, taotluse erialase hindamise tasu suurus taotluse eri liikide kaupa ning tasu arvestamise ja tasumise kord\u201d muutmine, <a data-url=\"https:\/\/www.riigiteataja.ee\/akt\/130112010003\" href=\"https:\/\/www.riigiteataja.ee\/akt\/130112010003\" target=\"_blank\" title=\"\" rel=\"noopener\">https:\/\/www.riigiteataja.ee\/akt\/130112010003<\/a> (04.09.19)\n\t<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Ameerika \u00dchendriikide Toidu ja Ravimiamet, Geneerilised ravimpreparaadid (Generic Drugs), https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/generic-drugs (04.09.19) Euroopa Direktiiv 2001\/83\/E\u00dc, https:\/\/eur-lex.europa.eu\/legal-content\/en\/ALL\/?uri=CELEX%3A32001L0083 (05.09.19) Euroopa Ravimiamet, geneerilised ravimpreparaadid (Generic and hybrid medicines), https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/generic-hybrid-medicines (04.09.19) Euroopa Ravimiamet, Head tootmistavad (Good Manufacturing Practice). https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-manufacturing-practice Euroopa Ravimiamet, Head kliiniliste uuringute tavad &#8230;<\/p>\n","protected":false},"author":142,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-20","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/pages\/20","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/users\/142"}],"replies":[{"embeddable":true,"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/comments?post=20"}],"version-history":[{"count":1,"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/pages\/20\/revisions"}],"predecessor-version":[{"id":207,"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/pages\/20\/revisions\/207"}],"wp:attachment":[{"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/media?parent=20"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}